Healthcare Affordability Under Scrutiny: Insurers Face Congress as Costs Soar
Amid rising concerns over healthcare accessibility, executives from five of the nation’s largest health insurance companies testified before Congress on Thursday, facing questions about the escalating cost of care for American families. The hearing comes as overall healthcare spending continues to climb, reaching $5.3 trillion in 2024 – representing 18% of the US gross domestic product.
Lawmakers Demand Answers on Rising Premiums
The House Energy and Commerce Committee convened the session, led by Chairman Brett Guthrie and subcommittee chair Morgan Griffith, as part of a broader Republican effort to address healthcare costs ahead of the 2026 midterm elections. Lawmakers expressed frustration over the lack of progress in renewing enhanced Affordable Care Act (ACA) subsidies, which have been credited with keeping premiums manageable during the COVID-19 pandemic.
According to a recent survey by the KFF health policy group, family premiums for employer-based insurance are projected to rise 6% in 2025, reaching nearly $27,000 annually. This increase underscores the urgency of finding solutions to make healthcare more affordable for millions of Americans.
UnitedHealth Group Announces ACA Profit Rebate
In a notable development during the hearing, Stephen Hemsley, CEO of UnitedHealth Group, announced the company will voluntarily rebate profits earned this year from its ACA plans to customers. However, Hemsley clarified that UnitedHealth is a “relatively small participant” in the ACA individual market.
“Though UnitedHealthcare is a relatively small participant in the individual ACA market, we will voluntarily eliminate and rebate our profits this year for these coverages, as Congress continues to work toward more long-term solutions,” Hemsley stated in prepared remarks.
Concerns Over Market Consolidation and Transparency
The hearing also highlighted concerns about the concentration of power within the health insurance industry. Griffith noted that the market is “dominated by a handful of Fortune 50 corporations” and “lacks transparency and is not easily navigable.” This sentiment was echoed by Representative Alexandria Ocasio-Cortez, who pointed to the consolidation of companies like CVS Caremark, which owns Aetna, CVS pharmacies, and some drug manufacturers.
“The health insurance gets a cut, the pharmacy benefits manager gets a cut, the drug manufacturer gets a cut and the patient gets screwed,” Ocasio-Cortez said, arguing that dismantling corporate monopolies is crucial for improving affordability. She suggested that addressing this issue has support across the political spectrum, uniting “capitalists and a card-carrying democratic socialists.”
Prescription Drug Costs and Coverage Decisions Under Fire
Representative Diana Harshbarger, a pharmacist, directly challenged the insurance executives on their decision-making processes regarding prescription drug coverage and pricing. She accused the companies of exerting undue control over the market.
“That’s not competition, that is control. And that isn’t just participating in the market, it’s running the rules of the market,” Harshbarger asserted.
Political Divides on ACA Subsidies and Future Solutions
The debate over the future of ACA subsidies remains a key point of contention. Former President Donald Trump has opposed restoring the subsidies, instead proposing direct payments to consumers through health savings accounts. However, his framework has been criticized for lacking specific details.
Democrats, meanwhile, are pushing to extend the enhanced premium tax credits that reduce ACA plan costs. The US House recently passed legislation to re-establish these credits after a bipartisan effort, but their long-term future remains uncertain. Without these subsidies, premiums are projected to double, potentially leading to a significant drop in coverage.
ACA Enrollment Trends Raise Concerns
Despite the efforts to maintain affordability, ACA enrollment numbers are showing signs of decline. While a record 24 million Americans purchased ACA plans last year, enrollment this year is lagging behind, with approximately 22.8 million people signed up so far – roughly 800,000 fewer than at the same point in 2024. Both new sign-ups and returning enrollees are down, signaling a potential challenge to the program’s continued success.
The congressional hearings mark the beginning of a broader series aimed at identifying solutions to reduce healthcare costs across the system, but the path forward remains unclear amidst political divisions and complex market dynamics.
Worth a look
